162 related articles for article (PubMed ID: 30898662)
1. Exploration of biomedical dendrimer space based on in-vitro physicochemical parameters: key factor analysis (Part 1).
Mignani S; Rodrigues J; Roy R; Shi X; Ceña V; El Kazzouli S; Majoral JP
Drug Discov Today; 2019 May; 24(5):1176-1183. PubMed ID: 30898662
[TBL] [Abstract][Full Text] [Related]
2. Exploration of biomedical dendrimer space based on in-vivo physicochemical parameters: Key factor analysis (Part 2).
Mignani S; Rodrigues J; Roy R; Shi X; Ceña V; El Kazzouli S; Majoral JP
Drug Discov Today; 2019 May; 24(5):1184-1192. PubMed ID: 30904723
[TBL] [Abstract][Full Text] [Related]
3. Dendrimer biocompatibility and toxicity.
Duncan R; Izzo L
Adv Drug Deliv Rev; 2005 Dec; 57(15):2215-37. PubMed ID: 16297497
[TBL] [Abstract][Full Text] [Related]
4. Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications.
Kalomiraki M; Thermos K; Chaniotakis NA
Int J Nanomedicine; 2016; 11():1-12. PubMed ID: 26730187
[TBL] [Abstract][Full Text] [Related]
5. Anionic linear-globular dendrimers: biocompatible hybrid materials with potential uses in nanomedicine.
Alavidjeh MS; Haririan I; Khorramizadeh MR; Ghane ZZ; Ardestani MS; Namazi H
J Mater Sci Mater Med; 2010 Apr; 21(4):1121-33. PubMed ID: 20082119
[TBL] [Abstract][Full Text] [Related]
6. Oligoethylenimine-grafted polypropylenimine dendrimers as degradable and biocompatible synthetic vectors for gene delivery.
Russ V; Günther M; Halama A; Ogris M; Wagner E
J Control Release; 2008 Dec; 132(2):131-40. PubMed ID: 18812195
[TBL] [Abstract][Full Text] [Related]
7. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications.
Kannan RM; Nance E; Kannan S; Tomalia DA
J Intern Med; 2014 Dec; 276(6):579-617. PubMed ID: 24995512
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in dendrimer-based nanomedicine development.
Kim Y; Park EJ; Na DH
Arch Pharm Res; 2018 Jun; 41(6):571-582. PubMed ID: 29450862
[TBL] [Abstract][Full Text] [Related]
9. On Forgotten Topological Indices of Some Dendrimers Structure.
Bashir Y; Aslam A; Kamran M; Qureshi MI; Jahangir A; Rafiq M; Bibi N; Muhammad N
Molecules; 2017 May; 22(6):. PubMed ID: 28538687
[TBL] [Abstract][Full Text] [Related]
10. PAMAM dendrimer - cell membrane interactions.
Fox LJ; Richardson RM; Briscoe WH
Adv Colloid Interface Sci; 2018 Jul; 257():1-18. PubMed ID: 30008347
[TBL] [Abstract][Full Text] [Related]
11. Interactions of dendrimers with biological drug targets: reality or mystery - a gap in drug delivery and development research.
Ahmed S; Vepuri SB; Kalhapure RS; Govender T
Biomater Sci; 2016 Jul; 4(7):1032-50. PubMed ID: 27100841
[TBL] [Abstract][Full Text] [Related]
12. Biological Activity of Mesoporous Dendrimer-Coated Titanium Dioxide: Insight on the Role of the Surface-Interface Composition and the Framework Crystallinity.
Milowska K; Rybczyńska A; Mosiolek J; Durdyn J; Szewczyk EM; Katir N; Brahmi Y; Majoral JP; Bousmina M; Bryszewska M; El Kadib A
ACS Appl Mater Interfaces; 2015 Sep; 7(36):19994-20003. PubMed ID: 26305597
[TBL] [Abstract][Full Text] [Related]
13. Influence of different generations of poly(propylene imine) dendrimers on human erythrocytes.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Dec; 65(12):891-5. PubMed ID: 21284258
[TBL] [Abstract][Full Text] [Related]
14. Biomedical applications of nano-antioxidant.
Watal G; Watal A; Rai PK; Rai DK; Sharma G; Sharma B
Methods Mol Biol; 2013; 1028():147-51. PubMed ID: 23740118
[TBL] [Abstract][Full Text] [Related]
15. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications.
Menjoge AR; Kannan RM; Tomalia DA
Drug Discov Today; 2010 Mar; 15(5-6):171-85. PubMed ID: 20116448
[TBL] [Abstract][Full Text] [Related]
16. Dendrimers for pharmaceutical and biomedical applications.
Yang H; Kao WJ
J Biomater Sci Polym Ed; 2006; 17(1-2):3-19. PubMed ID: 16411595
[TBL] [Abstract][Full Text] [Related]
17. Principal Physicochemical Methods Used to Characterize Dendrimer Molecule Complexes Used as Genetic Therapy Agents, Nanovaccines or Drug Carriers.
Alberto RFR; Joao R; de Los Angeles MM; Alberto MM; Manuel Jonathan FV; José CB
Curr Pharm Des; 2017 Aug; 23(21):3076-3083. PubMed ID: 28228073
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery.
Kesharwani P; Iyer AK
Drug Discov Today; 2015 May; 20(5):536-47. PubMed ID: 25555748
[TBL] [Abstract][Full Text] [Related]
19. Multivalent Copper(II)-Conjugated Phosphorus Dendrimers with Noteworthy
Mignani S; Shi X; Steinmetz A; Majoral JP
Mol Pharm; 2021 Jan; 18(1):65-73. PubMed ID: 33236637
[TBL] [Abstract][Full Text] [Related]
20. The evaluation of the biomedical effectiveness of poly(amido)amine dendrimers generation 4.0 as a drug and as drug carriers: a systematic review and meta-analysis.
Jędrych M; Borowska K; Galus R; Jodłowska-Jędrych B
Int J Pharm; 2014 Feb; 462(1-2):38-43. PubMed ID: 24374222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
